Sanofi invested 200 million yuan in insulin production base landing in Beijing.

Introduction: Sanofi (Beijing) Pharmaceutical Co., Ltd. "To Youssef (R) Project" into the zone agreement (insulin glycelin injection new preparation production line) signing ceremony was held in Beijing.
beijing, August 25, 2020 / Xinhua / - Sanofi (Beijing) Pharmaceutical Co., Ltd. "To excellent time ® project" entry agreement (insulin insulin insulin injection production line) signing ceremony held in Beijing, the project will be launched, will effectively alleviate the vast number of diabetics in China's insulin demand, while bringing innovative drugs and disease solutions for Chinese diabetics.
The signing ceremony was attended by Chen Xiaoman, Deputy Director of the Beijing Economic and Technological Development Zone Management Committee, Li Hong, Director of the Beijing Economic and Technological Development Zone Business Cooperation Bureau, Pius S. Hornstein, General Manager of Sanofi Pharmaceuticals Global Business Unit china and President of China.
Sanofi (Beijing) Pharmaceutical Co., Ltd." to Youssef (R) project "into the zone agreement signing ceremony" to Youssef ® Project" investment total amount of 200 million yuan, the project will be upgraded in the early stage of the existing production line, so that the existing production line has the ability to produce more varieties.
this basis, the new assembly and packaging production line, the assembly line is expected to start production in 2022 and filling in 2024.
production line with a fully automatic design, with a production capacity of up to 48 million units per year, will be exported to Australia and Japan as well as other Asia-Pacific regions while meeting the Needs of the Chinese market.
China is a large country with the largest population of diabetics in the world, according to the latest Chinese epidemiological study published this year, China's adult diabetes has reached 129 million people, according to the 2019 National Bureau of Statistics demographic data of 1.28 billion adults, an average of 1 diabetic in eight adults.
, diabetes has had a significant impact on the health and socio-economic development of our people, which is the most "sweet" burden.
However, the current situation of diabetes treatment in China is worrying, the overall diagnosis rate and treatment rate of diabetic patients in China is low, of which less than half of the patients (43.25%) were diagnosed, and less than half (48.95%) of the diabetics diagnosed were treated.
latest epidemiological data show that the blood sugar compliance rate of diabetics in China is less than half (49.41%).
more than 30% of people with diabetes in China have long-term use of insulin treatment, insulin use in diabetes is lower than in developed countries.
the future, with the improvement of basic medical care level and the increase of residents' income level, the increase in the actual number of patients will still greatly promote the growth of the demand for insulin drugs.
To address the difficulties faced by Chinese diabetic patients in the process of starting and daily use of insulin, and to help Chinese patients achieve better and safer blood sugar control and a better quality of life, the new preparation of insulin glycelin injections (registered trademark: Toujeo ®, Toujeo® and referred to as Eugene ® products) are currently being reviewed by the Drug Review Center of the State Drug Administration.
products have been launched in more than 82 countries and regions around the world, I believe that after the launch in China, will become a vast number of diabetics new treatment options.
.